查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953431

活體生物療法和微生物CDMO市場－全球產業規模、佔有率、趨勢、機會及預測（按應用、產品、製劑類型、規模、地區和競爭格局分類，2021-2031年）

Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Product, By Type of Formulation, By Scale of Operation, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物療法產品和微生物 CDMO 市場預計將從 2025 年的 332.2 億美元成長到 2031 年的 2,265.6 億美元，複合年成長率為 37.71%。

生物治療產品（LBP）利用活微生物來治療或預防疾病，這需要具備複雜厭氧發酵和製劑能力的專業合約研發生產機構（CDMO）。由於臨床研發管線不斷完善，以及生物製藥公司傾向於利用外部合作夥伴來應對複雜的生產流程而無需大量資本投入，該市場正在加速發展。此外，公共部門也積極推動這一領域的發展。例如，人類微生物組行動組織（Human Microbiome Action）報告稱，歐盟委員會已透過「地平線歐洲」（Horizo​​n Europe）計劃在2025年撥款約1億歐元，用於促進基於微生物組的解決方案的開發和應用。

市場概覽
預測期 2027-2031
市場規模：2025年 332.2億美元
市場規模：2031年 2265.6億美元
複合年成長率：2026-2031年 37.71%
成長最快的細分市場 臨床規模操作
最大的市場 北美洲

然而，缺乏統一的全球監管標準是市場發展的一大障礙。這種監管的不確定性使得標準化生產通訊協定和品管系統的建立變得複雜，阻礙了臨床試驗向商業化生產的順利過渡。最終，這種不確定性會延緩新產品的核准流程，並限制創新治療方法上市的速度。

市場促進因素

生物治療藥物臨床研發管線的快速擴張是推動市場成長的關鍵因素，也因此對能夠擴大複雜厭氧生產規模的合約研發生產機構（CDMO）產生了顯著需求。隨著候選藥物從早期發現階段進入後期臨床試驗，對高品質、符合GMP規範的臨床試驗材料的需求顯著增加，迫使研發人員利用外部生產資源。 Vedanta Biosciences等公司進入後期臨床試驗階段，尤其反映了這種成熟趨勢。該公司於2024年5月宣布，其採用口服細菌聯合療法的III期臨床實驗「RESTORATiVE303」已完成首例患者入組。

此外，對微生物組療法的資本投資和資金籌措不斷增加，為該領域提供了建設專業設施和開發穩定製劑技術所需的流動資金，從而推動了該領域的發展。這種資金支持不僅促進了生物技術創新，也證實了市場的商業性可行性，使企業能夠在無需承擔過高基礎設施成本的情況下外包生產。例如，Enterobiotics公司於2024年4月宣布已獲得2,700萬英鎊的資金籌措，用於進一步加強其臨床研發管線和生產能力。此外，商業性成功也推動了策略行動，例如Seres Therapeutics公司於2024年將其VOWST資產出售給雀巢健康科學公司，獲得1.55億美元的預付款，這凸顯了商業化所能實現的價值。

市場挑戰

全球監管標準的缺失對全球生物治療和微生物CDMO市場構成重大障礙。這種監管碎片化給研發企業和契約製造都帶來了巨大的不確定性，迫使他們應對不同地區的各種合規要求。由於生物治療產品依賴複雜的生物體，缺乏統一的框架使得生產製程和分析方法的檢驗日益困難，導致CDMO難以建立標準通訊協定。這增加了營運成本，並延長了技術轉移和規模化生產的時間。

因此，這種不確定的監管環境阻礙了強大的臨床研發管線向可上市治療方法的轉化。企業在從臨床試驗到大規模生產的過程中面臨著巨大的風險，因為不一致的指導方針往往需要耗費巨資重新設計流程以滿足不同的地區要求。這些瓶頸的嚴重性體現在創新成果難以轉化為核准療法。根據再生醫學聯盟（Alliance for Regenerative Medicine）2025年的數據，全球先進療法領域約75%的收入將來自不到10種上市產品，這凸顯了缺乏國際協調如何限制了廣泛的商業性成功。

市場趨勢

目前，市場格局正因一體化端到端服務模式的蓬勃發展而重塑。在這種模式下，合約研發生產機構（CDMO）整合了各項能力，並管理從菌株分離到商業填充和包裝的整個產品生命週期。這項變革的驅動力在於簡化複雜的供應鏈，並最大限度地降低在不同供應商之間轉移敏感厭氧生物材料所帶來的風險。透過提供統一的研發和生產服務，供應商可以縮短週期並確保產品的一致性。例如，Biose Industries, Inc. 在2024年12月的報告中指出，該公司生產超過600種細菌菌株，並已在全球範圍內交付了1000萬件成品，這充分展現了這種整合策略的規模。

同時，基因工程生物療法（eLBPs）的出現刺激了對高度專業化生產技術的需求，這些技術用於生產具有特定治療效果的改造生物體。與傳統的聯合療法不同，這些新一代治療方法需要先進的基因編輯工具和嚴格的生物安全防護通訊協定，迫使合約研發生產機構（CDMO）採用新的加工技術。這項技術進步能夠精準地改造微生物組，從而針對特定的疾病路徑。 Eligo Bioscience公司於2024年7月在《自然》雜誌上發表的一項突破性研究證實了其潛力，該研究展示了能夠以近乎完美的效率直接對腸道環境中的細菌進行基因改造。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球活體生物治療產品與微生物CDMO市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • （用於治療困難梭狀芽孢桿菌傳染病、克隆氏症、大腸激躁症、糖尿病等）
    • 依產品（原料藥、組合藥物）
    • 按劑型類型（固態劑型、口服液劑型、注射劑型、其他）
    • 依生產規模（臨床前生產規模、臨床生產規模、商業化生產規模）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美活體生物療法和微生物CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲活體生物療法和微生物CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區活體生物治療產品及微生物CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東及非洲活體生物治療產品及微生物CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲活體生物治療產品與微生物CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球活體生物治療產品與微生物CDMO市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Lonza Group Ltd.
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Samsung Biologics Co., Ltd.
  • Recipharm AB
  • Eurofins Scientific SE
  • AGC Biologics A/S
  • Boehringer Ingelheim International GmbH
  • Piramal Pharma Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15742

The Global Live Biotherapeutics Products and Microbe CDMO Market is projected to surge from USD 33.22 Billion in 2025 to USD 226.56 Billion by 2031, expanding at a CAGR of 37.71%. Because Live Biotherapeutic Products (LBPs) utilize live microorganisms to treat or prevent diseases, they require specialized Contract Development and Manufacturing Organizations (CDMOs) equipped to handle intricate anaerobic fermentation and formulation tasks. Market acceleration is fueled by a strengthening clinical pipeline and the tendency of biopharmaceutical firms to utilize external partners to navigate manufacturing complexities without significant capital expenditure. Furthermore, public sector initiatives are actively promoting this sector; for instance, Human Microbiome Action noted in 2025 that the European Commission allocated nearly €100 million through Horizon Europe to foster development and deployment of microbiome-based solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 33.22 Billion
Market Size 2031USD 226.56 Billion
CAGR 2026-203137.71%
Fastest Growing SegmentClinical Scale Operations
Largest MarketNorth America

However, the absence of harmonized global regulatory standards serves as a significant obstacle to market progress. This regulatory ambiguity complicates the creation of standardized manufacturing protocols and quality control systems, which hinders the smooth transition from clinical trials to commercial-scale production. Ultimately, these uncertainties can decelerate the approval process for new products, limiting the speed at which novel therapies reach the market.

Market Driver

A primary catalyst for market growth is the swift broadening of the global live biotherapeutic clinical pipeline, creating a critical need for CDMOs that can scale complex anaerobic manufacturing operations. As candidates advance from early discovery phases to late-stage pivotal trials, the requirement for high-quality, GMP-compliant clinical trial materials increases substantially, prompting developers to engage external manufacturing resources. This maturation is highlighted by companies entering advanced testing stages, such as Vedanta Biosciences, which announced in May 2024 that it had enrolled the first patient in its pivotal Phase 3 RESTORATiVE303 study for an orally administered bacterial consortium.

Additionally, rising capital investments and funding for microbiome-based therapies are driving the sector forward by providing necessary liquidity for building specialized facilities and improving stability-enhancing formulation technologies. This financial support not only fuels biotech innovation but also confirms the commercial viability of the market, enabling firms to outsource production without bearing prohibitive infrastructure costs. For example, EnteroBiotix announced in April 2024 that it had secured £27 million to further its clinical pipeline and manufacturing capabilities. Furthermore, commercial success drives strategic activity, as seen in 2024 when Seres Therapeutics sold its VOWST assets to Nestle Health Science for an upfront payment of $155 million, highlighting the value realized upon commercialization.

Market Challenge

The lack of harmonized global regulatory standards constitutes a major hurdle for the Global Live Biotherapeutics Products and Microbe CDMO Market. This regulatory fragmentation fosters deep uncertainty for both developers and contract manufacturers, who are forced to manage differing compliance mandates across various regions. Since live biotherapeutic products rely on complex biological organisms, the lack of a unified framework makes validating manufacturing processes and analytical methods increasingly difficult, causing CDMOs to struggle with establishing standard protocols, which raises operational costs and prolongs timelines for technology transfer and scaling.

Consequently, this uncertain regulatory landscape hampers the movement of a robust clinical pipeline toward becoming marketable therapies. Companies encounter significant risks when scaling from clinical trials to mass production, as inconsistent guidelines often demand costly process re-engineering to satisfy divergent regional requirements. The severity of these bottlenecks is illustrated by the difficulty in transforming innovation into approved treatments; according to the Alliance for Regenerative Medicine in 2025, roughly 75 percent of global revenue in the advanced therapy sector came from fewer than ten commercialized products, highlighting how a lack of international alignment restricts broader commercial success.

Market Trends

The market is currently being reshaped by the proliferation of integrated end-to-end service models, where CDMOs consolidate their capabilities to manage the full product lifecycle, spanning from strain isolation to commercial fill-finish. This evolution is motivated by the necessity to simplify complex supply chains and minimize risks involved in transferring sensitive anaerobic biological materials between different vendors. By providing unified development and manufacturing services, providers can hasten timelines and ensure consistency; for instance, Biose Industrie noted in its December 2024 report that it had manufactured over 600 bacterial strains and delivered 10 million finished products worldwide, showcasing the scale of this integrated strategy.

Concurrently, the emergence of genetically engineered live biotherapeutics (eLBPs) is stimulating demand for highly specialized manufacturing technologies designed to manage modified organisms with specific therapeutic payloads. Unlike traditional consortia, these next-generation treatments necessitate advanced genetic editing tools and strict containment protocols, compelling CDMOs to implement novel processing techniques. This technical progression enables precise microbiome modification to target specific disease pathways, a potential validated by Eligo Bioscience in July 2024 when they announced a landmark study in Nature demonstrating the ability to genetically modify bacteria directly within the gut environment with near-perfect efficiency.

Key Market Players

  • Lonza Group Ltd.
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Samsung Biologics Co., Ltd.
  • Recipharm AB
  • Eurofins Scientific SE
  • AGC Biologics A/S
  • Boehringer Ingelheim International GmbH
  • Piramal Pharma Limited

Report Scope

In this report, the Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Live Biotherapeutics Products and Microbe CDMO Market, By Application

  • C.difficle
  • Crohns disease
  • IBS
  • Diabetes
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Product

  • APIs
  • FDFs

Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation

  • Solid Formulations
  • Oral Liquids
  • Injectables
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Live Biotherapeutics Products and Microbe CDMO Market.

Available Customizations:

Global Live Biotherapeutics Products and Microbe CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
    • 5.2.2. By Product (APIs, FDFs)
    • 5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
    • 5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Product
    • 6.2.3. By Type of Formulation
    • 6.2.4. By Scale of Operation
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Type of Formulation
        • 6.3.1.2.4. By Scale of Operation
    • 6.3.2. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Type of Formulation
        • 6.3.2.2.4. By Scale of Operation
    • 6.3.3. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Type of Formulation
        • 6.3.3.2.4. By Scale of Operation

7. Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Product
    • 7.2.3. By Type of Formulation
    • 7.2.4. By Scale of Operation
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Type of Formulation
        • 7.3.1.2.4. By Scale of Operation
    • 7.3.2. France Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Type of Formulation
        • 7.3.2.2.4. By Scale of Operation
    • 7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Type of Formulation
        • 7.3.3.2.4. By Scale of Operation
    • 7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Type of Formulation
        • 7.3.4.2.4. By Scale of Operation
    • 7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Type of Formulation
        • 7.3.5.2.4. By Scale of Operation

8. Asia Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Product
    • 8.2.3. By Type of Formulation
    • 8.2.4. By Scale of Operation
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Type of Formulation
        • 8.3.1.2.4. By Scale of Operation
    • 8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Type of Formulation
        • 8.3.2.2.4. By Scale of Operation
    • 8.3.3. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Type of Formulation
        • 8.3.3.2.4. By Scale of Operation
    • 8.3.4. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Type of Formulation
        • 8.3.4.2.4. By Scale of Operation
    • 8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Type of Formulation
        • 8.3.5.2.4. By Scale of Operation

9. Middle East & Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Product
    • 9.2.3. By Type of Formulation
    • 9.2.4. By Scale of Operation
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Type of Formulation
        • 9.3.1.2.4. By Scale of Operation
    • 9.3.2. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Type of Formulation
        • 9.3.2.2.4. By Scale of Operation
    • 9.3.3. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Type of Formulation
        • 9.3.3.2.4. By Scale of Operation

10. South America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Product
    • 10.2.3. By Type of Formulation
    • 10.2.4. By Scale of Operation
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Type of Formulation
        • 10.3.1.2.4. By Scale of Operation
    • 10.3.2. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Type of Formulation
        • 10.3.2.2.4. By Scale of Operation
    • 10.3.3. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Type of Formulation
        • 10.3.3.2.4. By Scale of Operation

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Live Biotherapeutics Products and Microbe CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Lonza Group Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Catalent, Inc.
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 15.5. Samsung Biologics Co., Ltd.
  • 15.6. Recipharm AB
  • 15.7. Eurofins Scientific SE
  • 15.8. AGC Biologics A/S
  • 15.9. Boehringer Ingelheim International GmbH
  • 15.10. Piramal Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer